May 5, 2026 · Gynecologic oncology · DOI: 10.1016/j.ygyno.2026.04.012

Real-world monitoring and clinical management of decreased platelet counts in patients with epithelial ovarian cancer who received first-line maintenance niraparib in the ACTIV1ZE study

Listen to this summary

The authors aimed to investigate the frequency, onset, resolution, and clinical management of decreased platelet counts (DPCs) in patients with epithelial ovarian cancer receiving first-line maintenance niraparib. They found that DPCs occurred early in treatment, were resolved in the majority of cases, and were typically managed with dose modifications, leading to low treatment discontinuation rates. However, the absence of dose modifications in many patients who discontinued treatment suggests a need for improved clinical management strategies to enhance patient outcomes.

Fernanda B Musa, Tirza Areli Calderón Boyle, Jonathan T Lim, Julia Moore, Warsha K Singh, Jeanne M Schilder, Jean A Hurteau, Amanda K Golembesky, Lisa M Landrum

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play